Literature DB >> 362975

An analysis of the role of IgE in intolerance to aspirin and tartrazine.

J K Weltman, R P Szaro, G A Settipane.   

Abstract

Total serum IgE and eosinophil count were determined for 30 patients with intolerance to aspirin. Total IgE levels in the aspirin intolerant patients were similar to those expected in a non-atopic population. In contrast, total eosinophil count (TEC) tended to be elevated in the aspirin intolerant group. Elevated TEC was observed both in bronchospastic (57%) and in urticarial (25%) aspirin intolerance. Specific anti-aspiryl and anti-tartrazyl antibodies of the IgE class were assayed by the galactosidase immunosorbent test (GIST). IgE anti-aspiryl antibodies were possibly detected in one patient, but did not correlate with clinical intolerance to aspirin. It is unlikely that the clinical symptoms and the eosinophilia of intolerance to aspirin and tartrazine are mediated by antibodies of the IgE class.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 362975     DOI: 10.1111/j.1398-9995.1978.tb01548.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  5 in total

1.  Sensitivity to tartrazine.

Authors:  K Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-04

2.  Applicability and significance of salicylate screening in sera of voluntary blood donors: evaluation of two analytical methods.

Authors:  R Sharon; I Frutkoff; G Kidroni; J Menczel
Journal:  J Clin Pathol       Date:  1982-01       Impact factor: 3.411

3.  Tartrazine: a potentially hazardous dye in Canadian drugs.

Authors:  M E MacCara
Journal:  Can Med Assoc J       Date:  1982-04-15       Impact factor: 8.262

4.  Pathogenic Mechanisms and In Vitro Diagnosis of AERD.

Authors:  Dirk Schäfer; Steffen Maune
Journal:  J Allergy (Cairo)       Date:  2012-05-10

5.  Complete resolution of airway hyperresponsiveness in aspirin-sensitive asthmatic patients.

Authors:  H S Park
Journal:  Korean J Intern Med       Date:  1996-06       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.